Search Results
You are looking at 1 - 3 of 3 items for
- Author: Riccardo Vigneri x
- Refine by access: All content x
Search for other papers by Paolo Vigneri in
Google Scholar
PubMed
Search for other papers by Francesco Frasca in
Google Scholar
PubMed
Search for other papers by Laura Sciacca in
Google Scholar
PubMed
Search for other papers by Giuseppe Pandini in
Google Scholar
PubMed
Search for other papers by Riccardo Vigneri in
Google Scholar
PubMed
Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases. Because of their frequency, reciprocal influences – even minor influences – may have a major impact. Epidemiological studies clearly indicate that the risk of several types of cancer (including pancreas, liver, breast, colorectal, urinary tract, and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased. Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy, and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and anti-androgens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors. In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.
Search for other papers by Roberta Malaguarnera in
Google Scholar
PubMed
Search for other papers by Angelo Mandarino in
Google Scholar
PubMed
Search for other papers by Emanuela Mazzon in
Google Scholar
PubMed
Search for other papers by Veronica Vella in
Google Scholar
PubMed
Search for other papers by Piero Gangemi in
Google Scholar
PubMed
Search for other papers by Carlo Vancheri in
Google Scholar
PubMed
Search for other papers by Paolo Vigneri in
Google Scholar
PubMed
Search for other papers by Alessandra Aloisi in
Google Scholar
PubMed
Search for other papers by Riccardo Vigneri in
Google Scholar
PubMed
Search for other papers by Francesco Frasca in
Google Scholar
PubMed
Inactivation of p53 and p73 is known to promote thyroid cancer progression. We now describe p63 expression and function in human thyroid cancer. TAp63α is expressed in most thyroid cancer specimens and cell lines, but not in normal thyrocytes. However, in thyroid cancer cells TAp63α fails to induce the target genes (p21Cip1, Bax, MDM2) and, as a consequence, cell cycle arrest and apoptosis occur. Moreover, TAp63α antagonizes the effect of p53 on target genes, cell viability and foci formation, and p63 gene silencing by small interfering (si) RNA results in improved p53 activity. This unusual effect of TAp63α depends on the protein C-terminus, since TAp63β and TAp63γ isoforms, which have a different arrangement of their C-terminus, are still able to induce the target genes and to exert tumour-restraining effects in thyroid cancer cells. Our data outline the existence of a complex network among p53 family members, where TAp63α may promote thyroid tumour progression by inactivating the tumour suppressor activity of p53.
Search for other papers by Fiorenza Gianì in
Google Scholar
PubMed
Search for other papers by Giuseppe Pandini in
Google Scholar
PubMed
Search for other papers by Nunzio Massimo Scalisi in
Google Scholar
PubMed
Search for other papers by Paolo Vigneri in
Google Scholar
PubMed
Search for other papers by Carmine Fazzari in
Google Scholar
PubMed
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Marco Russo in
Google Scholar
PubMed
Search for other papers by Romilda Masucci in
Google Scholar
PubMed
Search for other papers by Antonino Belfiore in
Google Scholar
PubMed
Search for other papers by Gwabriella Pellegriti in
Google Scholar
PubMed
IC Crystallography Institute, National Research Council, CNR, Catania, Italy
Search for other papers by Riccardo Vigneri in
Google Scholar
PubMed
Thyroid cancer incidence is increased in volcanic areas where environment pollution biocontaminates residents. Tungsten (W) is the most increased heavy metal in drinking water of Mount Etna volcanic area where it exceeds the normal range in the urine of 27% inhabitants. The possible connection between increased tungsten and thyroid cancer has never been studied. We investigated in vitro the effect tungsten on both human thyrocytes in primary culture, thyrospheres (aggregates of stem/precursor thyroid cells) and thyrocytes differentiated from tungsten-exposed thyrospheres. Chronic exposure to low-dose (nanomolar range, as in the urines of volcanic area residents) soluble tungsten had major biological effects on thyroid stem/precursor cells, promoting growth with a biphasic (hormetic) dose-response and reducing apoptosis. No such effects were observed in mature thyrocytes. In addition, tungsten-exposed thyrospheres had abnormal expression of genes commonly altered also in thyroid cancer and increased activation of the DNA-repair proteins H2AX and 53BP1. Moreover, exposure to tungsten decreased thyrosphere differentiation, as indicated by the reduced expression of thyroid-specific genes in derived thyrocytes that also showed preneoplastic changes such as increased anchorage-independent growth, clonogenic growth and migration capacity. The mechanism of action of tungsten on thyroid stem/precursor cells is unclear but involves membrane G-proteins and activation of the ERK signaling pathway. These data indicate that chronic exposure to slightly increased tungsten, harmless for mature thyrocytes, importantly affects the biology of stem/precursor thyroid cells and of their progeny, inducing characteristics of preneoplastic transformation.
